Targets › KDM1A
4 programs from 4 companies in 19 trials: 8 Phase 2, 8 Phase 1, 3 Phase 3; Oncology; next expected readout Dec 2026.
Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. (UniProt, O60341)
Open in Phaseline: the race on KDM1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Bomedemstat (MK-3543) Lysine-specific histone demethylase 1 inhibitor | KDM1A | Phase 3 | Essential Thrombocythemia; Thrombocythemia, Essential; Polycythemia Vera; Acute Myeloid Leukemia | Jul 2027 |
| Daiichi Sankyo | Valemetostat Tosylate EZH1/2 dual inhibitor | EZH1, EZH2, KDM1A | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell … | Mar 2028 |
| Oryzon Genomics | Iadademstat LSD1 inhibitor | KDM1A | Phase 1 | Acute Myeloid Leukemia, in Relapse; Accelerated Phase Myeloproliferative Neoplasm; Acute Myeloid Leukemia; Extensive Stage Lung Small Cell Carcinoma … | Dec 2026 |
| M.D. Anderson Cancer Center | Seclidemstat LSD1 inhibitor | KDM1A | Phase 1 | Chronic Myelomonocytic Leukemia-0 | Sep 2027 |
Essential Thrombocythemia (3) Thrombocythemia, Essential (2) Acute Myeloid Leukemia (2) Polycythemia Vera (1) Acute Myeloid Leukemia, in Relapse (1) Accelerated Phase Myeloproliferative Neoplasm (1) Extensive Stage Lung Small Cell Carcinoma (1) Extensive Stage Small Cell Lung Cancer (ES-SCLC) (1) Relapsed/Refractory Peripheral T-Cell Lymphoma (1) Non-small Cell Lung Cancer (1) Advanced Solid Tumor (1) Lymphoma, B-Cell (1)
small molecule (3), mixed (1)
Merck & Co. (MSD) (1) Oryzon Genomics (1) Daiichi Sankyo (1) M.D. Anderson Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.